Ciplukan (Physalis Angulata Linn.) Extract Compounds Potential on High-Fat Diet Induced Nonalcoholic Fatty Liver Disease (NAFLD) for Liver Anti-Fibrotic Drug Development

IF 0.7 Q4 PHARMACOLOGY & PHARMACY

INDONESIAN JOURNAL OF PHARMACY Pub Date : 2023-09-11 DOI:10.22146/ijp.6259

Enny Rohmawaty, Sumartini Dewi, Aziiz Mardanarian Rosdianto, Hermin Aminah Usman, Ade Zuhrotun, Rini Hendriani, Yoga Windhu Wardhana, Savira Ekawardhani, Hesti Lina Wiraswati, Andri Reza Rahmadi, Nenny Agustanti, M. Begawan Bestari

{"title":"Ciplukan (Physalis Angulata Linn.) Extract Compounds Potential on High-Fat Diet Induced Nonalcoholic Fatty Liver Disease (NAFLD) for Liver Anti-Fibrotic Drug Development","authors":"Enny Rohmawaty, Sumartini Dewi, Aziiz Mardanarian Rosdianto, Hermin Aminah Usman, Ade Zuhrotun, Rini Hendriani, Yoga Windhu Wardhana, Savira Ekawardhani, Hesti Lina Wiraswati, Andri Reza Rahmadi, Nenny Agustanti, M. Begawan Bestari","doi":"10.22146/ijp.6259","DOIUrl":null,"url":null,"abstract":"An increasing percentage of people have or are at risk to develop the non-alcoholic fatty liver disease (NAFLD) worldwide. Fibrosis has also been identified as the most important predictor of prognosis in patients with NAFLD. Ciplukan (Physalis angulata Linn.) was reported to have antifibrotic potency in CCl4-induced liver fibrotic rats. This study was conducted to evaluate the antifibrotic effect of ciplukan extract through repairing the liver function, anti-inflammatory, and lowering cholesterol. The liver fibrosis model using 20% margarine was injected subcutaneously 8 times with a frequency of twice a week for 4 weeks in 35 male and 35 female Wistar strains which were divided into 7 groups. Furthermore, the rats were given Ciplukan extract (CPL) orally starting the 6th week of treatment with 2 different doses, namely 13.5 mg (CPL-1) and 27 mg (CPL-2) every day for 4 weeks. The histopathological changes of liver fibrosis was analyzed using Haematoxylin Eosin (HE) staining. Determination of serum IL-6 and TGF-β1 levels was carried out by the ELISA method. ALT and cholesterol levels were tested using a diagnostic kit. Single and multiple doses of ciplukan extract with or without standard therapy (Vitamin E) can reduce fibrotic scores up to 1.30±0.95 (p=0.001), TGF-β1 levels up to 24.20±2.02 ng/mL (p = 0.000), IL-6 levels up to 1.68±0.52 pg/mL (p=0.156), ALT levels up to 104.57±2.02 U/mL (p=0.001), and cholesterol levels up to 81, 07±2.02 mg/dL (p=0.000). Ciplukan herb ethanol extract was proven to have liver antifibrotic activity, which means it has potential as a liver fibrotic drug. The liver antifibrotic effect of Ciplukan herb was shown by a histopathological decrease in liver fibrosis scores accompanied by a decrease in TGF-β1, IL-6, ALT, and cholesterol levels. Keywords: Physalis angulata Linn (Ciplukan), liver fibrosis, NAFLD, ALT, Cholesterol, IL-6","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":"150 1","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.6259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

An increasing percentage of people have or are at risk to develop the non-alcoholic fatty liver disease (NAFLD) worldwide. Fibrosis has also been identified as the most important predictor of prognosis in patients with NAFLD. Ciplukan (Physalis angulata Linn.) was reported to have antifibrotic potency in CCl4-induced liver fibrotic rats. This study was conducted to evaluate the antifibrotic effect of ciplukan extract through repairing the liver function, anti-inflammatory, and lowering cholesterol. The liver fibrosis model using 20% margarine was injected subcutaneously 8 times with a frequency of twice a week for 4 weeks in 35 male and 35 female Wistar strains which were divided into 7 groups. Furthermore, the rats were given Ciplukan extract (CPL) orally starting the 6th week of treatment with 2 different doses, namely 13.5 mg (CPL-1) and 27 mg (CPL-2) every day for 4 weeks. The histopathological changes of liver fibrosis was analyzed using Haematoxylin Eosin (HE) staining. Determination of serum IL-6 and TGF-β1 levels was carried out by the ELISA method. ALT and cholesterol levels were tested using a diagnostic kit. Single and multiple doses of ciplukan extract with or without standard therapy (Vitamin E) can reduce fibrotic scores up to 1.30±0.95 (p=0.001), TGF-β1 levels up to 24.20±2.02 ng/mL (p = 0.000), IL-6 levels up to 1.68±0.52 pg/mL (p=0.156), ALT levels up to 104.57±2.02 U/mL (p=0.001), and cholesterol levels up to 81, 07±2.02 mg/dL (p=0.000). Ciplukan herb ethanol extract was proven to have liver antifibrotic activity, which means it has potential as a liver fibrotic drug. The liver antifibrotic effect of Ciplukan herb was shown by a histopathological decrease in liver fibrosis scores accompanied by a decrease in TGF-β1, IL-6, ALT, and cholesterol levels. Keywords: Physalis angulata Linn (Ciplukan), liver fibrosis, NAFLD, ALT, Cholesterol, IL-6

查看原文本刊更多论文

棘足鼠(Physalis Angulata Linn.)高脂肪饮食诱导的非酒精性脂肪肝(NAFLD)抗肝纤维化药物的提取化合物潜力

在世界范围内，患有或有患非酒精性脂肪性肝病(NAFLD)风险的人群比例越来越高。纤维化也被认为是NAFLD患者预后最重要的预测因素。据报道，Ciplukan (Physalis angulata Linn.)对ccl4诱导的肝纤维化大鼠具有抗纤维化作用。本研究从修复肝功能、抗炎、降低胆固醇等方面评价环嘌呤提取物的抗纤维化作用。将35只Wistar雄性菌株和35只雌性菌株分为7组，采用20%人造黄油皮下注射8次，频率为每周2次，连续4周。从治疗第6周开始，大鼠口服Ciplukan提取物(CPL)，每天13.5 mg (CPL-1)和27 mg (CPL-2)，连续4周。采用血红素伊红(HE)染色分析肝纤维化组织病理学变化。ELISA法测定血清IL-6、TGF-β1水平。使用诊断试剂盒检测ALT和胆固醇水平。单次和多次剂量的西普坎提取物加标准治疗(维生素E)或不加标准治疗可使纤维化评分降低1.30±0.95 (p=0.001)， TGF-β1水平降低至24.20±2.02 ng/mL (p=0.000)， IL-6水平降低至1.68±0.52 pg/mL (p=0.156)， ALT水平降低至104.57±2.02 U/mL (p=0.001)，胆固醇水平降低至81,07±2.02 mg/dL (p=0.000)。西普鲁坎草药乙醇提取物已被证明具有抗肝纤维化活性，这意味着它有潜力作为肝纤维化药物。Ciplukan的抗肝纤维化作用表现为肝纤维化评分的组织病理学降低，同时TGF-β1、IL-6、ALT和胆固醇水平降低。关键词:角Physalis (Ciplukan)，肝纤维化，NAFLD, ALT，胆固醇，IL-6

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

INDONESIAN JOURNAL OF PHARMACY PHARMACOLOGY & PHARMACY-

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.